Effect of adriamycin on experimental proliferative vitreoretinopathy in the rabbit.

Abstract

The cell injection model of proliferative vitreoretinopathy (PVR) in the rabbit was used to study the therapeutic value of intravitreal adriamycin (doxorubicin). Adriamycin in a dose of 10 nmol per eye, if injected at the same time as the cells, controls PVR. At the cell doses used, PVR is not affected if there is a time interval between cell and drug injection. Because of retinal toxicity, as evidenced by electroretinographic and histopathologic changes, the beneficial effects of adriamycin on membrane formation cannot be exploited at this time.

• Authors: M A Sunalp, P Wiedemann, N Sorgente, S J Ryan
• Journal: Experimental eye research (Exp Eye Res) Vol. 41 Issue 1 Pg. 105-15 (Jul 1985) ISSN: 0014-4835 [Print] England
• PMID: 4029281 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Doxorubicin

Topics

• Animals
• Dose-Response Relationship, Drug
• Doxorubicin (administration & dosage, therapeutic use, toxicity)
• Electroretinography
• Eye Diseases (drug therapy)
• Female
• Fibroblasts (drug effects)
• In Vitro Techniques
• Male
• Microscopy, Electron
• Mitosis (drug effects)
• Rabbits
• Retina (drug effects, ultrastructure)
• Retinal Detachment (prevention & control)
• Retinal Diseases (drug therapy, pathology)
• Vitreous Body